Re: Xu et al.: Endophthalmitis after intravitreal injection of vascular endothelial growth factor inhibitors (Ophthalmology. 2018;125:1279-1286)

Ophthalmology. 2018 Nov;125(11):e80-e81. doi: 10.1016/j.ophtha.2018.05.025.

Authors

Mohab Eldeeb¹, Omar Hegazy², Mohamed Ali Eldeeb³

Affiliations

¹ Department of Ophthalmology, St. Michael's Hospital, Toronto, Canada.
² Department of Ophthalmology, Ain Shams University, Cairo, Egypt.
³ Department of Ophthalmology, Samaya Specialized Center, Abu Dhabi, United Arab Emirates. Electronic address: meldeeb@eim.ae.

PMID: 30318046
DOI: 10.1016/j.ophtha.2018.05.025

No abstract available

Publication types

Letter
Comment

MeSH terms

Endophthalmitis*
Humans
Intravitreal Injections
Ranibizumab
Vascular Endothelial Growth Factor A*

Substances

Vascular Endothelial Growth Factor A
Ranibizumab